B
Merck & Co., Inc. MRK
$115.86 $0.610.53%
Recommendation
Buy
Prev Close
$115.86
Volume
6,709,621
Avg Vol (90D)
9,093,013
Market Cap
$293.68B
Dividend & Yield
$3.04(2.62%)
52-Week Range
$99.14 - $134.63
P/E (TTM)
21.51
EPS (TTM)
$5.39
My Lists My Alerts
Report
Rating
Reward
B+
Good
Risk
B-
Good
Rating Factors
Growth Index
Excellent
Efficiency Index
Excellent
Solvency Index
Excellent
Total Return Index
Fair
Volatility Index
Good
Dividend Index
Good
Headlines
KEYTRUDA (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
9/15/2024 - Business Wire
Ten-Year Data for Mercks KEYTRUDA (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
9/15/2024 - Business Wire
Is Merck & Co. (MRK) the Best Blue Chip Stock To Invest In According to Short Sellers?
9/14/2024 - Insider Monkey
KEYTRUDA (pembrolizumab) Plus LENVIMA (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
9/14/2024 - Business Wire
Mercks KEYTRUDA (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
9/14/2024 - Business Wire
Where Will Merck Stock Be in 5 Years?
9/14/2024 - Fool.com Headlines
KEYTRUDA (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
9/14/2024 - Business Wire
Merck (MRK) Increases Yet Falls Behind Market: What Investors Need to Know
9/13/2024 - Zacks Investment Research
Notable Friday Option Activity: VST, FND, MRK
9/13/2024 - Stock Options Channel
Merck & Co Unusual Options Activity
9/13/2024 - Benzinga
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts
9/13/2024 - Zacks Investment Research
AGF Management Ltd. Has $5.89 Million Holdings in Merck & Co., Inc. (NYSE:MRK)
9/13/2024 - Zolmax
12 Best Blue Chip Stocks To Invest In According to Short Sellers
9/13/2024 - Insider Monkey
Here's Why Merck (MRK) Gained But Lagged the Market Today
9/12/2024 - Zacks Investment Research
Ex-Dividend Reminder: Merck, CONMED and Extra Space Storage
9/12/2024 - Dividend Channel
Merck & Co., Inc. (NYSE:MRK) Shares Purchased by Strategic Financial Concepts LLC
9/12/2024 - Zolmax
Merck & Co., Inc. (NYSE:MRK) Shares Acquired by Strategic Financial Concepts LLC
9/12/2024 - Ticker Report
Is Merck & Co., Inc. (MRK) the Best Defensive Stock According to Reddit?
9/12/2024 - Insider Monkey
Bristol Myers Stock Rises 16% in 3 Months: Buy, Sell or Hold?
9/11/2024 - Zacks Investment Research
7 Best Stocks for Beginners with Little Money According to Analysts
9/11/2024 - Insider Monkey
Corvus Stock Up on Initiation of Phase III Lymphoma Study on Lead Drug
9/11/2024 - Zacks Investment Research
Merck to Participate in the Bank of America 2024 Global Healthcare Conference
9/11/2024 - Business Wire
Merck Announces Positive Top-line Results from Phase 3 Trial Evaluating Efficacy and Safety of GARDASIL9 in Japanese Males
9/11/2024 - Business Wire
Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
9/10/2024 - Zacks Investment Research
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
9/10/2024 - Zacks Investment Research
Income Statement
Total Revenue (TTM)
$62.48B
EBITDA (TTM)
$23.42B
EBIT (TTM)
$19.55B
Net Income (TTM)
$13.74B
Balance Sheet
Total Assets (Q)
$112.63B
Total Debt (Q)
$37.79B
Total Liabilities (Q)
$68.98B
Book Value Per Share (Q)
$17.19
Cash Flow
Cash from Operations (TTM)
$16.69B
Cash from Investing (TTM)
-$2.73B
Cash from Financing (TTM)
-$8.11B
Net Change in Cash (TTM)
$5.66B
Filings
Filing Date
Monday, August 5, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Beginning of November (est)
Price History
Loading...
Beta
-0.08
7-Day Total Return
-2.30%
30-Day Total Return
0.57%
60-Day Total Return
-10.65%
90-Day Total Return
-10.61%
Year to Date Total Return
3.58%
1-Year Total Return
9.15%
2-Year Total Return
39.59%
3-Year Total Return
74.23%
5-Year Total Return
71.28%
52-week Low
Oct 19, 2023 - $99.14
52-week High
Jun 25, 2024 - $134.63
Valuation
Market Cap
$293.68B - Mega Cap
Enterprise Value
$320.18B
Price/Sales (TTM)
4.72
Price/Book (Q)
6.74
Dividends and Shares
Shares Outstanding
2.54B
Dividend Per Share (Most Recent)
$0.77
Dividend Per Share (TTM)
$3.04
Corporate Info
Website
www.merck.com
Phone Number
908 740 4000
Address
126 East Lincoln Avenue
Rahway, NJ 07065
Country
United States
Year Founded
1891
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical... more
NYSE 09/13/2024 4:00PM Eastern Quotes delayed
Weiss Ratings